PMID- 26717976
OWN - NLM
STAT- MEDLINE
DCOM- 20161028
LR  - 20191210
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 35
IP  - 3
DP  - 2016 Mar
TI  - Expression and regulation of COP1 in chronic lymphocytic leukemia cells for 
      promotion of cell proliferation and tumorigenicity.
PG  - 1493-500
LID - 10.3892/or.2015.4526 [doi]
AB  - Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western 
      countries, and mainly originates from an accumulation of abnormal B cells caused 
      by the dysregulation of cell proliferation and apoptosis. The aberration of 
      proliferation-related gene in CLL cells induces cell arrest at G0/G1 phase, or a 
      small section shows rapid cell growth, which further complicates the pathogenesis 
      of CLL. The constitutively photomorphogenic 1 (COP1), as an E3 ubiquitin ligase, 
      is involved in many biological processes in mammalian cells, but its role in 
      chronic lymphocytic leukemia (CLL) progression remains unclear. In the present 
      study, we analyzed the expression of COP1 in peripheral blood mononuclear cells 
      (PBMCs) from 23 CLL patients and 3 healthy donors. The observed upregulated 
      expression of COP1 in CLL patients was positively correlated with CLL clinical 
      stage and ZAP-70 expression, but not del(13q14) and del(17q-). Overexpression of 
      COP1 significantly promoted cell colony formation and proliferation, especially 
      contributing to the accumulation of cells in S-phase by inhibition of FoxO1 and 
      p21. Moreover, overexpression of COP1 accelerated tumorigenicity of HG3 cells and 
      promoted xenograft growth. Therefore, the present study revealed that COP1 plays 
      an important role in CLL cell proliferation and tumorigenicity, and may be a 
      useful indicator of the chronic lymphocytic leukemia processes.
FAU - Fu, Chunling
AU  - Fu C
AD  - Blood Diseases Institute, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. 
      China.
FAU - Gong, Yanqing
AU  - Gong Y
AD  - Blood Diseases Institute, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. 
      China.
FAU - Shi, Xuanxuan
AU  - Shi X
AD  - Blood Diseases Institute, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. 
      China.
FAU - Shi, Hengliang
AU  - Shi H
AD  - Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical College, 
      Xuzhou, Jiangsu 221002, P.R. China.
FAU - Wan, Yan
AU  - Wan Y
AD  - Blood Diseases Institute, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. 
      China.
FAU - Wu, Qingyun
AU  - Wu Q
AD  - Blood Diseases Institute, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. 
      China.
FAU - Xu, Kailin
AU  - Xu K
AD  - Blood Diseases Institute, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151228
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (FOXO1 protein, human)
RN  - 0 (Forkhead Box Protein O1)
RN  - 0 (Forkhead Transcription Factors)
RN  - EC 2.3.2.27 (COP1 protein, human)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
RN  - EC 2.7.10.2 (ZAP-70 Protein-Tyrosine Kinase)
RN  - EC 2.7.11.1 (p21-Activated Kinases)
SB  - IM
MH  - Animals
MH  - Apoptosis/genetics
MH  - Carcinogenesis/*genetics
MH  - Cell Cycle Checkpoints/genetics
MH  - Cell Proliferation/*genetics
MH  - Chromosome Aberrations
MH  - Female
MH  - Forkhead Box Protein O1
MH  - Forkhead Transcription Factors/genetics
MH  - Gene Expression Regulation, Leukemic/genetics
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics/pathology
MH  - Leukocytes, Mononuclear/metabolism/pathology
MH  - Male
MH  - Mice
MH  - Ubiquitin-Protein Ligases/*biosynthesis/genetics
MH  - Xenograft Model Antitumor Assays
MH  - ZAP-70 Protein-Tyrosine Kinase/biosynthesis/genetics
MH  - p21-Activated Kinases/genetics
EDAT- 2016/01/01 06:00
MHDA- 2016/11/01 06:00
CRDT- 2016/01/01 06:00
PHST- 2015/10/11 00:00 [received]
PHST- 2015/11/18 00:00 [accepted]
PHST- 2016/01/01 06:00 [entrez]
PHST- 2016/01/01 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
AID - 10.3892/or.2015.4526 [doi]
PST - ppublish
SO  - Oncol Rep. 2016 Mar;35(3):1493-500. doi: 10.3892/or.2015.4526. Epub 2015 Dec 28.